de Jong Anno, Youala Myriam, El Garch Farid, Simjee Shabbir, Rose Markus, Morrissey Ian, Moyaert Hilde
CEESA ComPath Study Group, 168 Av de Tervueren, 1150, Brussels, Belgium.
IHMA Europe Sàrl, 1870, Monthey, Switzerland.
Vet Dermatol. 2020 Dec;31(6):431-e114. doi: 10.1111/vde.12886. Epub 2020 Sep 13.
The ComPath project is a pan-European programme dedicated to the monitoring of antimicrobial susceptibility of canine and feline pathogens using standardized methods and centralized minimal inhibitory concentration (MIC) determination.
To report antimicrobial susceptibilities of major pathogens isolated from nontreated animals with acute clinical signs of skin, wound or ear infections in 2013-2014.
MICs were determined by agar dilution for commonly used drugs and interpreted using Clinical and Laboratory Standards Institute (CLSI) breakpoints, if available.
Of 1,676 isolates recovered, the main species isolated from dogs were Staphylococcus pseudintermedius, followed by Streptococcus spp., Pseudomonas aeruginosa and Escherichia coli. In cats, Pasteurella multocida, coagulase-negative staphylococci (CoNS) and Staphylococcus aureus were isolated most frequently. Resistance rates observed for S. pseudintermedius were <26.7% for penicillin, clindamycin and chloramphenicol, and ≤11.5% for ampicillin, amoxicillin/clavulanate, cefalexin, cefovecin, gentamicin and fluoroquinolones. For S. aureus, resistance rates ranged up to 90.9% for β-lactams, and were 19.7% for clindamycin, 27% for fluoroquinolones and 0.0-6.1% for other drugs. The mecA gene was confirmed by PCR in 10.6% of S. pseudintermedius, 11.6% of CoNS and 31.4% of S. aureus isolates. In streptococci/enterococci, resistance to penicillin, ampicillin and chloramphenicol ranged from 0.0% to 11.3%, whereas fluoroquinolone resistance ranged from 0.0% to 8.5%. For E. coli, resistance ranged from 13.8 to 15.9% for fluoroquinolones and from 86.2% to 100.0% for β-lactams. Low rates of resistance (0.0-6.3%) were observed in P. multocida, and for P. aeruginosa resistance to gentamicin was 10.3%.
Overall, antimicrobial resistance of cutaneous/otic pathogens isolated from dogs and cats was low (1-10%) to moderate (10-20%). For several pathogens, the paucity of CLSI recommended breakpoints for veterinary use is a bottleneck.
ComPath项目是一项泛欧洲计划，致力于使用标准化方法和集中式最低抑菌浓度（MIC）测定来监测犬猫病原体的抗菌药物敏感性。
报告2013 - 2014年从有皮肤、伤口或耳部感染急性临床症状的未经治疗动物中分离出的主要病原体的抗菌药物敏感性。
对于常用药物，通过琼脂稀释法测定MIC，并在可行的情况下使用临床和实验室标准协会（CLSI）的断点进行解释。
在回收的1676株分离菌中，从狗身上分离出的主要菌种是中间型假单胞菌，其次是链球菌属、铜绿假单胞菌和大肠杆菌。在猫中，多杀巴斯德菌、凝固酶阴性葡萄球菌（CoNS）和金黄色葡萄球菌是最常分离出的菌种。观察到中间型假单胞菌对青霉素、克林霉素和氯霉素的耐药率<26.7%，对氨苄西林、阿莫西林/克拉维酸、头孢氨苄、头孢维星、庆大霉素和氟喹诺酮类药物的耐药率≤11.5%。对于金黄色葡萄球菌，β-内酰胺类药物的耐药率高达90.9%，克林霉素为19.7%，氟喹诺酮类为27%，其他药物为0.0 - 6.1%。通过PCR在10.6%的中间型假单胞菌、11.6%的CoNS和31.4%的金黄色葡萄球菌分离株中证实了mecA基因。在链球菌/肠球菌中，对青霉素、氨苄西林和氯霉素的耐药率为0.0%至11.3%，而氟喹诺酮类药物的耐药率为0.0%至8.5%。对于大肠杆菌，氟喹诺酮类药物的耐药率为13.8%至15.9%，β-内酰胺类药物的耐药率为86.2%至100.0%。多杀巴斯德菌的耐药率较低（0.0 - 6.3%），铜绿假单胞菌对庆大霉素的耐药率为10.3%。
总体而言，从狗和猫身上分离出的皮肤/耳部病原体的抗菌药物耐药性为低（1 - 10%）至中度（10 - 20%）。对于几种病原体，CLSI推荐的兽用断点缺乏是一个瓶颈。
